Nippon Shinyaku Co., Ltd. (NIPPON SHINYAKU CO) aksje

Nippon Shinyaku Co., Ltd. manufactures and sells pharmaceuticals and foodstuffs in Japan and internationally. The company operates through Pharmaceuticals and Functional Food Business segments. It offers drugs in the fields of urology, hematology, intractable and rare diseases, gynecology, and other diseases; health food ingredients, preservatives, protein preparations, and supplements. The company in the Strategic Partnership with Nippon Shinyaku to develop ATSN-10 that is in Phase I/II of clinical trials for the treatment of GUCY2D-mutant Leber congenital amaurosis; and RGX-121 for the treatment of mucopolysaccharidosis. Nippon Shinyaku Co., Ltd. was founded in 1911 and is headquartered in Kyoto, Japan.